Arun Pasumarthy
About Arun Pasumarthy
Arun Pasumarthy serves as the Business Development Manager at Virogin Biotech in Vancouver, Canada, where he has worked since 2024. He has a background in biotechnology and finance, with previous roles at J.P. Morgan and DICO Group, and has contributed significantly to strategic alliances in the biotech sector.
Current Role at Virogin Biotech
Arun Pasumarthy serves as the Business Development Manager at Virogin Biotech, a position he has held since 2024. Based in Vancouver, British Columbia, Canada, he has been with the company for 8 months. In this role, he oversees alliance management and drives five active research collaborations with both national and international partners. His responsibilities include identifying potential partners at research and partnering conferences to maximize the platform's potential and drive innovation.
Previous Experience in Biotech and Finance
Before joining Virogin Biotech, Arun Pasumarthy accumulated extensive experience in the biotech and finance sectors. He worked at J.P. Morgan as an Analyst in Biotech Equity Research from 2015 to 2019 and later as an Associate for 6 months in 2019. He also served as an Investment Banking Analyst at Verity Knowledge Solutions Pvt. Ltd. from 2014 to 2015 and as an Equity Analyst at DICO Group from 2020 to 2022. His roles involved conducting market research and competitive intelligence in the healthcare and technology sectors.
Educational Background
Arun Pasumarthy has a strong educational foundation in biotechnology and finance. He earned a Dual Degree (B.Tech & M.Tech) in Biotechnology from the Indian Institute of Technology, Madras, from 2009 to 2014. He also studied MPC (Mathematics, Physics & Chemistry) at Narayana College, completing his high school education from 2007 to 2009. Additionally, he has passed CFA Level 2, having studied Accounting and Finance at the CFA Institute.
Strategic Contributions to Virogin Biotech
During his tenure at Virogin Biotech, Arun Pasumarthy played a pivotal role in establishing a strategic alliance with MD Anderson Cancer Center. This collaboration significantly accelerated the clinical development of product candidates. He leads efforts in gathering competitive intelligence and conducting market research to evaluate novel payloads, tumor-associated antigens (TAAs), and technologies of interest, contributing to the company's innovation and growth.